Viking Therapeutics: Expecting Further Upside In 2018
(WorldNews Health)

Viking Therapeutics (VKTX) had quite an incredible three months, rising around 250% on the heels of positive clinical results and successfully accessing additional financing from institutional investors. While the stock may seem overly elevated to some, I remind readers that the valuation looks reasonable considering they are still significantly in the red when examining a longer time frame. VKTX data by YCharts Recently the company announced a reasonable secondary offering whereby 5,130,435 shares of common stock were sold at a price point of $2.50 per share (expected proceeds of around $12.8 million). This was a notable improvement over their prior $15.0 million common stock purchase...